Literature DB >> 29266564

Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF.

Sean D Pokorney1,2, Sana M Al-Khatib1,2, Jie-Lena Sun2, Phillip Schulte3, Christopher M O'Connor4, John R Teerlink5, Paul W Armstrong6, Justin A Ezekowitz7, Randall C Starling8, Adriaan A Voors9, Eric J Velazquez1,2, Adrian F Hernandez1,2, Robert J Mentz1,2.   

Abstract

AIMS: The incidence of and factors associated with sudden cardiac death (SCD) early after an acute heart failure (HF) hospital admission have not been well defined. METHODS AND
RESULTS: We assessed SCD and ventricular arrhythmias in the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial, which included patients with acute HF with reduced or preserved ejection fraction. SCD, resuscitated SCD (RSCD), and sustained ventricular tachycardia/ventricular fibrillation (VT/VF) were adjudicated from randomization through 30 days and were combined into a composite endpoint. Baseline characteristics associated with this composite were determined by logistic regression. RSCD and VT/VF were included as time-dependent variables in a Cox model evaluating the association of these variables with 180-day all-cause mortality. Among 7011 patients, the 30-day all-cause mortality rate was 3.8%; SCD accounted for 17% of these deaths. The 30-day composite event rate was 1.8% (n = 121). Ten patients had more than one event with 30-day Kaplan-Meier event rates of 0.6% for SCD [95% confidence interval (CI) 0.5%-0.9%, n = 43], 0.4% for RSCD (95% CI 0.2%-0.5%, n = 24), and 0.9% for VT/VF (95% CI 0.7%-1.2%, n = 64). In the multivariable model, chronic obstructive pulmonary disease, history of VT, male sex, and longer QRS duration were associated with SCD, RSCD, or VT/VF. A RSCD or VT/VF event was associated with higher 180-day mortality (adjusted hazard ratio 6.6, 95% CI 4.8-9.1, P < 0.0001).
CONCLUSIONS: Approximately 2% of patients admitted for acute HF experienced SCD, RSCD, or VT/VF within 30 days of admission, and SCD accounted for 17% of all deaths within 30 days.
© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.

Entities:  

Keywords:  Heart failure; Implantable cardioverter-defibrillator; Sudden cardiac death; Ventricular fibrillation; Ventricular tachycardia

Mesh:

Substances:

Year:  2017        PMID: 29266564     DOI: 10.1002/ejhf.1078

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  11 in total

1.  Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial).

Authors:  Muthiah Vaduganathan; Ravi B Patel; Robert J Mentz; Haris Subacius; Neal A Chatterjee; Stephen J Greene; Andrew P Ambrosy; Aldo P Maggioni; James E Udelson; Karl Swedberg; Marvin A Konstam; Christopher M O'Connor; Javed Butler; Mihai Gheorghiade; Faiez Zannad
Journal:  Am J Cardiol       Date:  2018-04-11       Impact factor: 2.778

2.  Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes?

Authors:  Andrew P Ambrosy; Craig S Parzynski; Daniel J Friedman; Marat Fudim; Adrian F Hernandez; Gregg C Fonarow; Frederick A Masoudi; Sana M Al-Khatib
Journal:  Circulation       Date:  2018-12-11       Impact factor: 29.690

3.  Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial.

Authors:  João Pedro Ferreira; Abhinav Sharma; Cyrus Mehta; George Bakris; Patrick Rossignol; William B White; Faiez Zannad
Journal:  Clin Res Cardiol       Date:  2020-08-13       Impact factor: 5.460

Review 4.  Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines.

Authors:  Anna Levinsson; Marie-Pierre Dubé; Jean-Claude Tardif; Simon de Denus
Journal:  ESC Heart Fail       Date:  2018-06-19

5.  Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes.

Authors:  Sarah A Goldstein; Robert J Mentz; Anne S Hellkamp; Tiffany C Randolph; Gregg C Fonarow; Adrian Hernandez; Clyde W Yancy; Sana M Al-Khatib
Journal:  Clin Cardiol       Date:  2018-12-26       Impact factor: 2.882

Review 6.  Highlights in heart failure.

Authors:  Daniela Tomasoni; Marianna Adamo; Carlo Mario Lombardi; Marco Metra
Journal:  ESC Heart Fail       Date:  2019-12

7.  In-hospital ventricular arrhythmia in heart failure patients: 7 year follow-up of the multi-centric HEARTS registry.

Authors:  Basel Alenazy; Shabana Tharkar; Tarek Kashour; Khalid Faiz Alhabib; Hussam Alfaleh; Ahmad Hersi
Journal:  ESC Heart Fail       Date:  2019-11-21

8.  Heart rate and blood pressure monitoring in heart failure.

Authors:  Piotr Ponikowski; Ilaria Spoletini; Andrew J S Coats; Massimo F Piepoli; Giuseppe M C Rosano
Journal:  Eur Heart J Suppl       Date:  2019-12-31       Impact factor: 1.803

Review 9.  Palliative Care in Acute Heart Failure.

Authors:  James M Beattie; Irene J Higginson; Theresa A McDonagh
Journal:  Curr Heart Fail Rep       Date:  2020-10-29

10.  Ventricular arrhythmias in patients with functional mitral regurgitation and implantable cardiac devices: implications of mitral valve repair with Mitraclip®.

Authors:  Tomás Benito-González; Xavier Freixa; Cosmo Godino; Maurizio Taramasso; Rodrigo Estévez-Loureiro; Daniel Hernandez-Vaquero; Ana Serrador; Luis Nombela-Franco; David Grande-Prada; Ignacio Cruz-González; Rodolfo San Antonio; Michele Galasso; Mara Gavazzoni; Carmen Garrote; Antonio Portolés-Hernández; Pablo Avanzas; Felipe Fernández-Vázquez; Isaac Pascual
Journal:  Ann Transl Med       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.